The ErbB receptors and their role in cancer progression

Holbro, Thomas; Civenni, Gianluca; Hynes, Nancy E.

doi:10.1016/s0014-4827(02)00099-x

Cited by 541 publications

(302 citation statements)

References 117 publications

Supporting

Mentioning

294

Contrasting

Unclassified

Order By: Relevance

“…The epidermal growth factor receptor (EGFR) is frequently overexpressed in lung cancer [1], and its kinase domain is a target of tyrosine kinase inhibitors (TKIs) [2,3]. Recently, activating mutations in the tyrosine kinase domain of EGFR were found to be strongly associated with the clinical response to EGFR-TKIs [4,5,6].…”

Section: Introductionmentioning

confidence: 99%

The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer

et al. 2012

View full text Add to dashboard Cite

Objectives: Cytological examination of samples obtained by bronchoscopy is a useful method for establishing the diagnosis of non-small cell lung cancer (NSCLC). However, the utility of a highly sensitive method for the detection of epidermal growth factor receptor (EGFR) mutation in the cytological specimens has not been fully evaluated. Methods: We retrospectively examined the efficacy of the peptide nucleic acid-locked nucleic acid polymerase chain reaction (PNA-LNA PCR) clamp method for detecting EGFR mutations in 122 bronchoscopic cytological specimens from NSCLC patients. Results: Overall, 41 specimens (33.6%) were positive for EGFR mutation. Twenty-nine (39.7%) of 73 specimens obtained by using endobronchial ultrasonography with a guide sheath, 7 (33.3%) of 21 specimens obtained under direct vision by using a conventional bronchoscope, 4 (36.4%) of 11 specimens obtained by using an ultrathin bronchoscope, and 1 (5.9%) of 17 specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration were positive for EGFR mutation. Furthermore, among 22 resected NSCLC cases, the EGFR mutation status obtained from bronchoscopic materials was consistent with the status obtained from surgical samples, with the exception of 1 case. Conclusion: The detection of EGFR mutation by subjecting bronchoscopic cytological specimens to a PNA-LNA PCR clamp assay proves useful.

show abstract

Section: Introductionmentioning

confidence: 99%

The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…EGF regulates normal and tumor cell proliferation via EGF receptor (EGFR) phosphorylation, homo- or heterodimerization and activation of mitogen-activated protein kinases (MAPKs) and PI3K/Akt pathways [81,82]. Expression of EGFR in NET is variable ranging from <20 to 86% depending on tumor type and method [41,76,83,84,85,86].…”

Section: Targeting Growth Factor Receptorsmentioning

confidence: 99%

Translation of Molecular Pathways into Clinical Trials of Neuroendocrine Tumors

Pavel

2012

Neuroendocrinology

View full text Add to dashboard Cite

Current treatment options for neuroendocrine tumors (NET) include somatostatin analogs, interferon-α, peptide receptor-targeted therapy and cytotoxic chemotherapy. Most patients undergo sequential therapies since these drugs are active only in subpopulations of patients and for a limited period of time. There is a need for novel drugs that are capable of amelioration of symptomatology (syndromic control) and/or tumor growth control. A number of diverse signaling pathways are involved in the pathogenesis of NET and tumor growth, thus many potential targets are available for drug targeting. Targeted therapies therefore represent an appropriate developmental therapeutic strategy given the multiplicity of potential targets in NET. These include but are not limited to: inhibitory or activating G protein-coupled receptors, receptor tyrosine kinases, ligands, and intracellular targets such as the mammalian target of rapamycin (mTOR). Numerous drugs that utilize single or multiple targets are currently in clinical development. Recently, two target-directed agents, the multiple tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus, have been approved for the treatment of progressive pancreatic NET. This review provides a broad overview of established and potential molecular targets in NET, summarizes data from phase II and III clinical trials with targeted drugs and outlines future therapeutic directions.

show abstract

“…Hierbei führte die Kombinati on von Bevacizumab und Paclitaxel beim HER2/neunegativen Mammakarzinom im Vergleich zur Monotherapie nicht nur zu einer Steigerung der Remissionrate, sondern auch zu einer Verdopplung der rezidivfreien Zeit (11,8 vs. 5,9 Monate). Die mediane Überlebenszeit wurde dage gen nicht günstig beeinflusst [20].…”

Section: E2100unclassified

Antikörper und Tyrosinkinaseinhibitoren

Herr

Bekes

2010

Gynäkologe

View full text Add to dashboard Cite

The ErbB receptors and their role in cancer progression

Cited by 541 publications

References 117 publications

The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer

The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer

Translation of Molecular Pathways into Clinical Trials of Neuroendocrine Tumors

Antikörper und Tyrosinkinaseinhibitoren

Contact Info

Product

Resources

About